Promoting Hematopoiesis with Chinese Medicinal Herbs: A Novel Therapy for Myelosuppression

What is it about?

Myelosuppression represents a common and severe complication of cancer chemotherapy. Current therapeutic regimens primarily target downstream hematopoietic progenitor cells rather than hematopoietic stem cells (HSCs), frequently resulting in the depletion of hematopoietic reserves. Furthermore, their high cost and requirement for parenteral administration render them unsuitable for preventive or long-term management. To address these limitations, we have developed nanovesicles derived from Epimedium that alleviate chemotherapy-induced myelosuppression. When administered orally, these nanovesicles activate the "gut-lactate-bone marrow" axis to promote hematopoietic stem cell proliferation and restore hematopoietic function.

Featured Image

Photo by Konstantinos Papadopoulos on Unsplash

Photo by Konstantinos Papadopoulos on Unsplash

Why is it important?

This study demonstrates that ENVs derived from the traditional medicinal herb Epimedium promote HSCs proliferation and restore bone marrow function through a "gut–lactate–bone marrow" axis. These findings provide a robust theoretical and experimental foundation for applying traditional Chinese medicine in hematopoietic recovery. As a safe and broadly applicable therapeutic strategy, ENVs hold significant clinical translation potential, offering a safer, more durable, and cost-effective treatment option for chemotherapy-treated cancer patients.

Perspectives